Azidopamil

Azidopamil
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Azidopamil is a chemical compound that has been studied for its potential pharmacological effects, particularly in the context of cardiovascular research. It is a derivative of verapamil, a well-known calcium channel blocker used in the treatment of hypertension and angina.

Chemical Structure and Properties

Azidopamil is structurally related to verapamil, with modifications that include the introduction of an azido group. This modification is intended to explore the effects of azido substitution on the pharmacological activity of the parent compound.

Pharmacodynamics

Azidopamil, like verapamil, is believed to act as a calcium channel blocker. Calcium channel blockers are a class of medications that disrupt the movement of calcium through calcium channels. They are used to treat high blood pressure, angina, and some arrhythmias. By blocking calcium channels, azidopamil may reduce the force of contraction of the heart muscle and dilate blood vessels, leading to a decrease in blood pressure.

Pharmacokinetics

The pharmacokinetic profile of azidopamil has not been extensively studied. However, it is expected to share some similarities with verapamil, which is known for its high first-pass metabolism and variable bioavailability. Further studies would be required to determine the absorption, distribution, metabolism, and excretion of azidopamil.

Clinical Research

As of the latest updates, azidopamil has not been approved for clinical use and remains a compound of interest primarily in research settings. Studies have focused on its potential cardiovascular effects, but more research is needed to fully understand its efficacy and safety profile.

Potential Applications

The primary interest in azidopamil lies in its potential as a cardiovascular agent. Researchers are investigating whether the azido modification could offer advantages over existing calcium channel blockers in terms of efficacy, side effects, or specific therapeutic applications.

Safety and Toxicology

The safety profile of azidopamil is not well-documented, as it has not undergone extensive clinical testing. As with any investigational compound, thorough toxicological studies are necessary to assess its safety for potential therapeutic use.

Also see

• Verapamil
• Calcium channel blocker
• Hypertension
• Angina
• Cardiovascular pharmacology